Green Cross to conduct phase III trial for Peramivir
Published: 2008-12-10 06:56:00
Updated: 2008-12-10 06:56:00
Green Cross Corporation plans to conduct its local phase III trials with peramivir injection, an important potential therapy for both seasonal influenza and pandemic preparedness as the Korea Food and Drug Administration has recently approved the clinical trial.
Develped by the US based BioCry...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
